SERGIO ALMEIDA DE OLIVEIRA
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Cardio-Pneumologia, Faculdade de Medicina - Docente
6 resultados
Resultados de Busca
Agora exibindo 1 - 6 de 6
- Early Increase in Myocardial Perfusion After Stem Cell Therapy in Patients Undergoing Incomplete Coronary Artery Bypass Surgery(2011) GOWDAK, Luis Henrique Wolff; SCHETTERT, Isolmar Tadeu; ROCHITTE, Carlos Eduardo; LISBOA, Luiz Augusto Ferreira; DALLAN, Luis Alberto Oliveira; CESAR, Luiz Antonio Machado; OLIVEIRA, Sergio Almeida de; KRIEGER, Jose EduardoIncomplete revascularization is associated with worse long-term outcomes. Autologous bone marrow cells (BMC) have recently been tested in patients with severe coronary artery disease. We tested the hypothesis that intramyocardial injection of autologous BMC increases myocardial perfusion in patients undergoing incomplete coronary artery bypass grafting (CABG). Twenty-one patients (19 men), 59 +/- 7 years old, with limiting angina and multivessel coronary artery disease (CAD), not amenable to complete CABG were enrolled. BMC were obtained prior to surgery, and the lymphomonocytic fraction separated by density gradient centrifugation. During surgery, 5 mL containing 2.1 +/- 1.3 x 10(8) BMC (CD34+ = 0.8 +/- 0.3%) were injected in the ischemic non-revascularized myocardium. Myocardial perfusion was assessed by magnetic resonance imaging (MRI) at baseline and 1 month after surgery. The increase in myocardial perfusion was compared between patients with < 50% (group A, n = 11) with that of patients with > 50% (group B, n = 10) of target vessels (stenosis a parts per thousand yenaEuro parts per thousand 70%) successfully bypassed. Injected myocardial segments included the inferior (n = 12), anterior (n = 7), and lateral (n = 2) walls. The number of treated vessels (2.3 +/- 0.8) was significantly smaller than the number of target vessels (4.2 +/- 1.0; P < 0.0001). One month after surgery, cardiac MRI showed a similar reduction (%) in the ischemic score of patients in group A (72.5 +/- 3.2), compared to patients in group B (78.1 +/- 3.2; P = .80). Intramyocardial injection of autologous BMC may help increase myocardial perfusion in patients undergoing incomplete CABG, even in those with fewer target vessels successfully treated. This strategy may be an adjunctive therapy for patients suffering from a more advanced (diffuse) CAD not amenable for complete direct revascularization.
bookPart Prefácio do volume(2016) OLIVEIRA, Sérgio Almeida debookPart Cirurgia cardíaca na doença coronariana aguda(2016) OLIVEIRA, Marco Antonio Praça; JUDAS, Gustavo Ieno; OLIVEIRA, Sérgio Almeida de- Additional improvement in regional myocardial ischemia after intracardiac injection of bone marrow cells during CABG surgery(2023) GOWDAK, Luis Henrique Wolff; SCHETTERT, Isolmar Tadeu; ROCHITTE, Carlos Eduardo; CARVALHO, Leonardo P. de; VIEIRA, Marcelo Luiz Campos; DALLAN, Luis Alberto Oliveira; OLIVEIRA, Sergio Almeida de; CESAR, Luiz Antonio Machado; BRITO, Jose Oscar Reis; GUARITA-SOUZA, Luiz Cesar; CARVALHO, Antonio Carlos Campos de; KRIEGER, Jose EduardoBackground: Post-procedure residual ischemia is associated with worse prognosis in patients with coronary artery diasease (CAD).Objective: We evaluated whether autologous bone marrow-derived cells (BMC) contribute to additional reduction in regional stress-induced myocardial ischemia (SIMI) in patients undergoing incomplete coronary artery bypass graft surgery (CABG).Methods: In a double-blind, randomized, placebo-controlled trial, we enrolled 143 patients (82% men, 58 & PLUSMN; 11 years) with stable CAD and not candidates for complete CABG. They received 100 million BMC (n = 77) or placebo (n = 66) injected into ischemic non-revascularized segments during CABG. The primary outcome was improvement on SIMI quantified as the area at risk in injected segments assessed by cardiovascular magnetic resonance (CMR) 1, 6, and 12 months after CABG.Results: The reduction in global SIMI after CABG was comparable (p = 0.491) in both groups indicating sustained beneficial effects of the surgical procedure over 12 month period. In contrast, we observed additional improvement in regional SIMI in BMC treated group (p = 0.047). Baseline regional SIMI values were comparable [18.5 (16.2-21.0) vs. 18.5 (16.5-20.7)] and reached the lowest values at 1 month [9.74 (8.25; 11.49) vs. 12.69 (10.84; 14.85)] for BMC and placebo groups, respectively. The ischemia's improvement from baseline represented a 50% difference in regional SIMI in favor of the BMC transplanted group at 30 days. We found no differences in clinical and LVEF% between groups during the 12 month follow-up period. The 1 month rate of major adverse cerebral and cardiovascular events (MACCE) (p = 0.34) and all-cause mortality (p = 0.08) did not differ between groups 1 month post intervention.Conclusion: We provided evidence that BMC leads to additional reduction in regional SIMI in chronic ischemic patients when injected in segments not subjected to direct surgical revascularization. This adjuvant therapy deserves further assessment in patients with advanced CAD especially in those with microcirculation dysfunction.
article 5 Citação(ões) na Scopus Long term results of septal myectomy in the treatment of obstructive hypertrophic cardiomyopathy(2011) LISBOA, Luiz Augusto Ferreira; DALLAN, Luis Alberto Oliveira; POMERANTZEFF, Pablo Maria Alberto; OLIVEIRA, Sergio Almeida de; JATENE, Fabio Biscegli; STOLF, Noedir Antonio GroppoObjectives: This study analyzed the clinical and echocardiographic late outcomes of surgical septal myectomy in patients with obstructive hypertrophic cardiomyopathy (OHCM). Methods: We examined, retrospectively, 34 consecutive adult patients (age 55.7 +/- 15.2 years) with OHCM operated on in our institution from 1988 to 2008. Only four (11.8%) patients had family history of OHCM. Nine (26.5%) patients were in New York Heart Association (NYHA) funcional class IV. Thirty (88.2%) patients had solely OHCM, and four (11.8%) had OHCM associated with coronary insufficiency. The surgical technique used in all patients was septal myectomy performed through an aortotomy. Results: In 26 (76.5%) patients the mitral insufficiency due to systolic anterior motion, decreased after the myectomy. Eight (23.5%) patients had mitral valve procedures. There was one hospitalar death (2.9%). Two (5.9%) patients required permanent pacemaker for complete heart block after the myectomy. The mean peak preoperative left ventrilcular outflow tract (LVOT) obstruction gradient was 84.9 +/- 29.0 mmHg, and decreased to 27.8 +/- 12.9 mmHg in the early postoperative and it was 19.2 +/- 11.2 mmHg in the late postoperative period (49.0 +/- 33.0 months). The NYHA functional class improved from 3.1 +/- 0.8 to 1.4 +/- 0.5 in the postoperative period. Survival free from death was 87.9% and survival free from cardiovascular events was 77.7% with mean follow-up 9.6 +/- 8.4 years. Conclusions: Surgical septal myectomy can be performed safely, with excellent survival, improvement from symptoms and relief for LVOT obstruction in patients with OHCM. The early benefits were remained at long term.conferenceObject Double-Blind, Placebo-Controlled, Randomized Trial of Stem Cell Therapy Combined With Bypass Surgery - The MiHeart Trial(2018) GOWDAK, Luis Henrique W.; SCHETTERT, Isolmar T.; MENEGHETTI, Jose Claudio; ROCHITTE, Carlos Eduardo; DALLAN, Luis Alberto O.; GUARITA-SOUZA, Luiz Cesar; BRITO, Jose Oscar R.; CESAR, Luiz Antonio M.; OLIVEIRA, Sergio A. de; CARVALHO, Antonio Carlos C. de; KRIEGER, Jose Eduardo